Price Alert

Amneal Pharmaceuticals In... (AMRX)

NASDAQ: AMRX · Real-Time Price · USD

9.56

0.01 (0.10%)

At close: Sep 05, 2025, 11:35 AM

Amneal Pharmaceuticals Statistics

Share Statistics

Amneal Pharmaceuticals has 314.08M shares outstanding. The number of shares has increased by 50.39% in one year.

Shares Outstanding	314.08M
Shares Change (YoY)	50.39%
Shares Change (QoQ)	0.01%
Owned by Institutions (%)	43.22%
Shares Floating	144.96M
Failed to Deliver (FTD) Shares	1
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 4.78M, so 1.52% of the outstanding shares have been sold short.

Short Interest	4.78M
Short % of Shares Out	1.52%
Short % of Float	2.36%
Short Ratio (days to cover)	2.49

Valuation Ratios

The PE ratio is -20.94 and the forward PE ratio is 10.6. Amneal Pharmaceuticals's PEG ratio is 1.

PE Ratio	-20.94
Forward PE	10.6
PS Ratio	0.88
Forward PS	0.9
PB Ratio	-22.4
P/FCF Ratio	10.06
PEG Ratio	1

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Amneal Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.41, with a Debt / Equity ratio of -23.73.

Current Ratio	1.41
Quick Ratio	0.86
Debt / Equity	-23.73
Debt / EBITDA	5.9
Debt / FCF	10.66
Interest Coverage	0.96

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$336.62K
Profits Per Employee	$-14.08K
Employee Count	8,300
Asset Turnover	0.8
Inventory Turnover	2.9

Taxes

Income Tax	18.86M
Effective Tax Rate	-34.29%

Stock Price Statistics

The stock price has increased by 13.02% in the last 52 weeks. The beta is 1.12, so Amneal Pharmaceuticals's price volatility has been higher than the market average.

Beta	1.12
52-Week Price Change	13.02%
50-Day Moving Average	8.6
200-Day Moving Average	8.14
Relative Strength Index (RSI)	67.27
Average Volume (20 Days)	1,625,161

Income Statement

In the last 12 months, Amneal Pharmaceuticals had revenue of 2.79B and earned -116.89M in profits. Earnings per share was -0.38.

Revenue	2.79B
Gross Profit	1.02B
Operating Income	249.33M
Net Income	-116.89M
EBITDA	439.77M
EBIT	203.58M
Earnings Per Share (EPS)	-0.38

Full Income Statement

Balance Sheet

The company has 110.55M in cash and 2.59B in debt, giving a net cash position of -2.48B.

Cash & Cash Equivalents	110.55M
Total Debt	2.59B
Net Cash	-2.48B
Retained Earnings	-607.06M
Total Assets	3.42B
Working Capital	477.56M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 295.1M and capital expenditures -51.92M, giving a free cash flow of 243.18M.

Operating Cash Flow	295.1M
Capital Expenditures	-51.92M
Free Cash Flow	243.18M
FCF Per Share	0.79

Full Cash Flow Statement

Margins

Gross margin is 36.52%, with operating and profit margins of 8.92% and -4.18%.

Gross Margin	36.52%
Operating Margin	8.92%
Pretax Margin	-1.97%
Profit Margin	-4.18%
EBITDA Margin	15.74%
EBIT Margin	8.92%
FCF Margin	8.7%

Dividends & Yields

AMRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AMRX is $11.5, which is 20.4% higher than the current price. The consensus rating is "Buy".

Price Target	$11.5
Price Target Difference	20.4%
Analyst Consensus	Buy
Analyst Count	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.85
Piotroski F-Score	8